What oral antibiotic regimen is appropriate for a patient with a urinary tract infection caused by non‑ESBL‑producing Escherichia coli who is allergic to azithromycin?

Oral Antibiotic Treatment for Non-ESBL E. coli UTI with Azithromycin Allergy

For a urinary tract infection caused by non-ESBL E. coli in a patient with azithromycin allergy, use nitrofurantoin 100 mg twice daily for 5 days as first-line therapy, or alternatively fosfomycin trometamol 3 g as a single dose for uncomplicated cystitis. 1

Clinical Context and Azithromycin Relevance

The azithromycin allergy mentioned is clinically irrelevant to UTI treatment. Azithromycin is not a recommended agent for E. coli urinary tract infections 2. The FDA labeling indicates azithromycin is used for respiratory infections, sexually transmitted infections (urethritis, cervicitis), and skin infections—not UTIs 2. Research confirms azithromycin's role is limited to nongonococcal urethritis syndrome, not E. coli UTIs 3. Therefore, this allergy does not restrict your treatment options.

Treatment Algorithm Based on UTI Classification

For Uncomplicated Cystitis (Lower UTI):

First-line options 1:

• Nitrofurantoin: 100 mg twice daily for 5 days (monohydrate/macrocrystals or prolonged-release formulation)
• Fosfomycin trometamol: 3 g single dose (women only)
• Pivmecillinam: 400 mg three times daily for 3-5 days (if available)

Second-line alternatives 1:

• Trimethoprim-sulfamethoxazole (TMP-SMX): 160/800 mg twice daily for 3 days
  • Only use if local E. coli resistance is <20%
  • Avoid in first trimester of pregnancy
• Cephalosporins (e.g., cefadroxil 500 mg twice daily for 3 days)
  • Only if local E. coli resistance <20%

Treatment duration: The 2024 guidelines clearly recommend 5 days for nitrofurantoin and 3 days for TMP-SMX or pivmecillinam 4, 1.

For Uncomplicated Pyelonephritis (Upper UTI):

Oral empiric therapy 1:

• Ciprofloxacin: 500-750 mg twice daily for 7 days
• Levofloxacin: 750 mg once daily for 5 days
• TMP-SMX: 160/800 mg twice daily for 14 days (if susceptible)
• Cefpodoxime: 200 mg twice daily for 10 days
• Ceftibuten: 400 mg once daily for 10 days

Critical caveat: Fluoroquinolones should only be used if local resistance is <10% 1. An initial IV dose of ceftriaxone should be given if using oral cephalosporins empirically 1.

Avoid: Nitrofurantoin, oral fosfomycin, and pivmecillinam have insufficient efficacy data for pyelonephritis 1.

For Complicated UTI:

Treatment depends on severity and patient factors 1:

• Mild-moderate cases: Oral fluoroquinolones or TMP-SMX for 7 days (based on susceptibilities)
• Severe cases or hospitalization: IV therapy with fluoroquinolones, cephalosporins (ceftriaxone 1-2 g daily, cefepime 1-2 g twice daily), or piperacillin-tazobactam 2.5-4.5 g three times daily 1

Key Clinical Considerations

Resistance patterns matter: Recent data shows E. coli maintains 96% susceptibility to fosfomycin globally 5 and high susceptibility to nitrofurantoin. However, fluoroquinolone resistance is increasing (only 21.9% susceptibility in one 2025 study) 6, making them less reliable for empiric therapy.

Non-ESBL status is favorable: Since this is non-ESBL E. coli, you have broader options. Third-generation cephalosporins remain effective (65.8-76.3% susceptibility) 6, though first-line agents are preferred to preserve these for resistant organisms.

Gender-specific considerations:

• For women with uncomplicated cystitis, all first-line options are appropriate 1
• For men, use TMP-SMX 160/800 mg twice daily for 7 days (longer duration than women) 1

Common pitfall: Do not use fluoroquinolones or second-generation cephalosporins as first-line empiric therapy due to rising resistance rates 6. Reserve fluoroquinolones for pyelonephritis when local susceptibility data supports their use.

Post-treatment: Routine follow-up cultures are unnecessary if symptoms resolve 1. Only reculture if symptoms persist or recur within 2 weeks, then treat for 7 days with a different agent 1.